Skip to main content

Table 1 Diagnostic and prognostic performance of SHOX2 and SEPT9 hypermethylation

From: Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients

Cohort Biomarker Quantification method Sens. (%) Spec. (%) AUC Hazard ratio P value 95% CI
Training
  SEPT9 Relative 63 90 0.80 1.23 < 0.001 1.11–1.35
Absolute 61 90 0.80 1.27 < 0.001 1.14–1.42
Quasi-digital PCR 62 92 0.79 1.90 < 0.001 1.34–2.69
SHOX2 Relative 57 90 0.81 1.14 0.009 1.03–1.26
Absolute 55 90 0.80 1.16 0.013 1.03–1.31
Quasi-digital PCR 53 87 0.78 1.85 0.008 1.18–2.91
Mean SEPT9/SHOX2 Relative 64 90 0.84 1.19 0.001 1.07–1.32
Absolute 64 90 0.83 1.22 0.001 1.08–1.37
Quasi-digital PCR 65 91 0.81 1.89 0.001 1.28–2.79
Testing
  SEPT9 Relative 56 88 0.74 1.22 0.002 1.07–1.38
Absolute 54 89 0.74 1.35 0.001 1.45–1.59
Quasi-digital PCR 55 90 0.75 1.67 0.010 1.13–2.45
SHOX2 Relative 48 93 0.79 1.15 0.045 1.00–1.31
Absolute 43 94 0.78 1.24 0.007 1.06–1.44
Quasi-digital PCR 43 95 0.77 1.71 0.032 1.05–2.80
Mean SEPT9/SHOX2 Relative 58 94 0.80 1.12 0.006 1.06–1.39
Absolute 49 90 0.80 1.30 0.001 1.11–1.53
Quasi-digital PCR 58 88 0.80 1.77 0.009 1.15–2.72
  1. Clinical performance was evaluated in HNSCC patients included in a training and a testing cohort. Methylation levels were calculated using three different algorithms (relative, absolute quantification, and quasi-digital PCR). Sensitivities (sens.), specificities (spec.), Area Under the Curve (AUC) of the Receiver Operating Characteristic, and Cox Proportional Hazards with univariate analysis of SEPT9, SHOX2, and mean SEPT9/SHOX2 , corresponding p values, and 95% confidence intervals are reported